# Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension

> **NCT00553267** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 947 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** fixed dose combination of telmisartan+amlodipine
- **DRUG:** amlodipine

## Key facts

- **NCT ID:** NCT00553267
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-10
- **Final completion:** —
- **Target enrollment:** 947 (ACTUAL)
- **Last updated:** 2014-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553267, "Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00553267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*